The total return over the past 12 months is -16.21% vs. +15.54% for the S&P 500. So far it's up +5.72% this year. Includes price appreciation + reinvested dividends.
| Category | 1Y (TTM) | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Price CAGR | (16.21%) | +6.88% | (13.01%) | N/A | N/A | N/A |
| Total Return CAGR | (16.21%) | +6.88% | (13.01%) | N/A | N/A | N/A |
| Revenue CAGR | (64.15%) | (57.13%) | +37.32% | +24.33% | N/A | N/A |
| Net Income CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| EPS CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Dividends CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
Visualize historical growth rates over rolling horizons. Use the dropdown to select different metric vectors.
CRISPR Therapeutics AG (CRSP)
| Year | Start price | End price | CRSP Return | SPY Return | Outperformance |
|---|---|---|---|---|---|
| 2026(YTD) | $52.44 | $55.44 | +5.72% | +12.91% | (7.19%) |
| 2025 | $39.36 | $52.44 | +33.23% | +17.72% | +15.51% |
| 2024 | $62.60 | $39.36 | (37.12%) | +24.89% | (62.01%) |
| 2023 | $40.65 | $62.60 | +54.00% | +26.19% | +27.81% |
| 2022 | $75.78 | $40.65 | (46.36%) | (18.17%) | (28.19%) |
| 2021 | $153.11 | $75.78 | (50.51%) | +28.74% | (79.25%) |
| 2020 | $60.91 | $153.11 | +151.39% | +18.37% | +133.02% |
| 2019 | $28.57 | $60.91 | +113.18% | +31.22% | +81.96% |
| 2018 | $23.48 | $28.57 | +21.68% | (4.56%) | +26.24% |
| 2017 | $20.26 | $23.48 | +15.89% | +21.70% | (5.81%) |
Start and end prices are split-adjusted closing prices. Total return includes reinvested dividends, so it can differ from the price change.
